Please login to the form below

Not currently logged in
Email:
Password:

Ariad appoints new board member

Alexander Denner is chief investment officer of Sarissa Capital Management
Ariad Alexander Denner

Ariad Pharmaceuticals has appointed Alexander Denner to the company's board of directors.

Denner is currently chief investment officer of investment firm Sarissa Capital Management and has served as senior managing director at Icahn Capital and as portfolio manager at both Viking Global Investors and Morgan Stanley Investment Management.

His pharma experience includes director roles at Biogen Idec and Vivus.

Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib).

The drug was approved at the end of 2012 in the US and in 2013 in the EU, although later faced safety reviews in both regions after it was linked to the development of blood clots.

Both the FDA and EMA concluded that the drug should continue to be available although with updated safety information.

Ariad also announced that another director is due to join the board, bringing the total number of board members to 10.

25th February 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....